I agree with your post SC.
The reason for the cost of product is that the TRIPP study is funded by the company, as is the percutaneous study so those treatments don't earn revenue. I kinda hope they can recoup that in the R&D reimbursement
I agree with your post SC.The reason for the cost of product is...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.04 |
Change
0.010(0.97%) |
Mkt cap ! $14.79M | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.04 | $1.00 | $37.49K | 37.31K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17640 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 1250 | 1 |
View Market Depth
| Last trade - 14.44pm 20/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |